Key points for investors:
- Strong Q1 operational and financial performance: 11% sales growth, 72.7% gross margin (up ~350 bps YoY), and 42% growth in diluted EPS ($0.68). Operating margin expanded to 27% and operating income rose 41% YoY. Cash from operations was $15.1M; quarter-end cash & securities totaled $367M. CapEx in Q1 was $2.8M.
- Artegraft is now the company’s largest product and a major growth driver: worldwide Artegraft sales grew 36% in Q1. International Artegraft sales were $2.1M in Q1 and management expects full-year 2026 Artegraft sales of $10M (vs. $4M in 2025). Health Canada approval received with a planned H2 2026 launch; additional approvals (Korea, Brazil, Vietnam, India) expected in 2027. Company plans filings in H2 2026 to support longer graft packaging (longer lengths) with potential first sales of longer sizes in H2 2027. A pre-submission has been made to the FDA to pursue “Quick Stick” AV access labeling for Artegraft (timeline uncertain and could be multi-year).
- RestoreFlow Allografts (RFA) momentum and geographic expansion: RFA grew 25% in Q1. Germany implants expected to begin in Q2; Irish approval and warehouse audit expected in H2 enabling Irish distribution; filings planned in Australia (filed April) and in several additional European countries in 2026. Tissue processing transfer to Burlington is progressing, expected complete by year-end.
- Commercial build and go-direct expansion: Salesforce ended Q1 at 158 reps (up 3% YoY) with a plan to finish 2026 at 170–180 reps. Company expects to go direct in Poland (32nd direct country) in Q4. Export/distribution business has shown multi-year strength and is a source of markets to convert to direct sales.
- Margin and efficiency drivers: Q1 margin expansion driven primarily by higher ASPs, favorable product mix (Artegraft growth), distribution softness last year, and manufacturing efficiencies/lean initiatives and improved logistics (warehouse footprint). Q2 gross margin guidance is 72.1% reflecting some near-term transfer/warehouse impacts; full-year gross margin guidance increased to 72.3%.
- Guidance and capital allocation: Management re-affirmed/raised 2026 targets: revenue guidance $280M (≈12% organic growth), operating income guidance $79.8M (≈24% growth vs adjusted 2025), and increased diluted EPS guidance to $3.00 (≈26% growth). Management continues dividend payments ($5.7M paid in Q1) and maintains a strong cash position for opportunistic M&A.
- M&A strategy and discipline: Management states they are actively pursuing acquisitions (term sheets out), focused on niche, physician-preference products in open vascular and targeted cardiac surgery niches with a revenue sweet spot ~$15M–$150M. They remain selective and patient on valuation/fit.
- Risks and timeline caveats: Artegraft Quick Stick regulatory pathway could take 2–5+ years; longer Artegraft sizes require packaging/filing work (filings planned H2 2026; sales earliest H2 2027). RestoreFlow rollout timing depends on regulatory audits and country-specific approvals. Geopolitical events had minimal impact so far (noted one ~$175k export hold), but supply/transportation costs could rise if disruptions persist.
Overall takeaways: LeMaitre showed broad-based organic growth, margin expansion, and strong cash generation in Q1 with Artegraft and RFA as key growth engines. Management is investing to scale Artegraft internationally (including product variations and labeling upgrades), expanding the sales organization and European logistics footprint, while remaining disciplined on M&A and focused on profitability and dividends. The company reaffirmed and modestly increased 2026 financial guidance, reflecting confidence in continued margin leverage and growth.
Sign In
Buy LMAT
